Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 7/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17366554 | 0.97 | DRD2 (0.65) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL17364137 | 0.89 | DRD2 (0.75) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL29354894 | 0.89 | DRD2 (0.75) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL28644153 | 0.86 | DRD2 (0.73) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL17368147 | 0.84 | DRD2 (0.67) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL25690904 | 0.81 | DRD2 (0.62) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| Pridopidine SCHEMBL29664816 | 0.77 | DRD2 (1.00) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| Pridopidine SCHEMBL166748 | 0.77 | DRD2 (1.00) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL25614171 | 0.76 | DRD2 (0.56) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| Pridopidine SCHEMBL15007479 | 0.76 | DRD2 (0.97) | DRD2SIGMAR1DRD3HTR6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2024-07-16 | — | — | US | disclosed |
| US-20230355595-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | US | disclosed |
| US-20230330073-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| US-20230181548-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-06-15 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355595-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | HTT, PARK7, DRD1 | DRD2 4/4885SIGMAR1 377/4885DRD3 25/4885 |
| US-20230181548-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PDE12, PDE3A, PDE3B | DRD2 16/4885SIGMAR1 341/4885DRD3 44/4885 |
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | SLC6A3, QDPR, PARK7 | DRD2 5/4885SIGMAR1 1492/4885DRD3 29/4885 |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 14/4885DRD3 5/4885 |
| US-20230330073-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | HTT, HYPK, PARK7 | DRD2 4/4885SIGMAR1 268/4885DRD3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.